Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
News about Teva Pharmaceutical Industries Limited (TEVA) focuses on its transformation into an innovative biopharmaceutical company, its generics and biosimilars franchise, and developments across neuroscience and immunology. Company announcements highlight progress on its Pivot to Growth strategy, including updates on branded medicines such as AUSTEDO, AJOVY and UZEDY, as well as late-stage pipeline assets.
Recent news includes clinical and regulatory milestones for AJOVY (fremanezumab-vfrm), where Phase 3 SPACE trial results in children and adolescents with episodic migraine were published in the New England Journal of Medicine. These data supported U.S. FDA approval for preventive treatment of episodic migraine in pediatric patients who meet specified criteria, adding to AJOVY’s existing indication in adults. News items provide details on trial design, efficacy outcomes, and safety profile.
Investors and followers of TEVA can also find updates on pipeline programs such as olanzapine extended-release injectable suspension (TEV-'749) for schizophrenia and the anti‑IL‑15 antibody TEV-'408 for vitiligo and celiac disease, including regulatory submissions and funding agreements. Teva’s news flow covers biosimilar approvals and collaborations, such as European Commission approvals for denosumab biosimilars PONLIMSI and DEGEVMA and the U.S. settlement and license agreement for AVT06, a proposed biosimilar to Eylea.
In addition, TEVA news features financial and capital markets events, including rating agency actions, amendments to credit facilities, quarterly earnings release dates, conference call schedules, and participation in major healthcare conferences. This mix of clinical, regulatory, strategic and financial updates makes the TEVA news page a central resource for tracking how Teva’s generics base, innovative pipeline and biosimilars portfolio contribute to its stated Pivot to Growth strategy. Users interested in TEVA stock can monitor this page for ongoing disclosures that may inform their understanding of the company’s operations and strategic direction.
Teva Pharmaceutical Industries Ltd. has agreed in principle on the primary financial terms of a nationwide opioids settlement, revising its provision to reflect this. The company reported Q2 2022 revenues of $3.8 billion, with a GAAP diluted loss per share of $0.21 and a non-GAAP diluted EPS of $0.68. The 2022 revenue outlook has been revised down to $15.0 - $15.6 billion, mainly due to foreign exchange headwinds and increased competition for COPAXONE®, which is now expected to generate around $700 million. The company aims to finalize the settlement documentation soon.
Teva Pharmaceuticals has reached a settlement with the City and County of San Francisco regarding opioid-related claims, providing $24.8 million over 13 years and $20 million worth of generic Narcan over 10 years. This settlement, while not an admission of liability, aims to deliver life-saving treatments for opioid addiction. Previously, a California Superior Court judge found that Teva did not cause a public nuisance related to opioids in several counties. Teva continues to pursue a nationwide settlement in the interest of those benefiting from its medicines.
Teva Pharmaceutical Industries Ltd. announced the appointment of Eric A. Hughes as Executive Vice President, Global R&D and Chief Medical Officer, effective August 1, 2022. Dr. Hughes brings nearly 20 years of experience in drug development, previously serving at Vertex Pharmaceuticals and Novartis. His expertise in leading clinical development and collaborations is expected to enhance Teva's Global R&D initiatives. CEO Kåre Schultz expressed gratitude to former executive Dr. Hafrun Fridriksdottir for her 25 years of service while highlighting the potential growth opportunities with Dr. Hughes's leadership.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will release its second quarter 2022 financial results on July 27, 2022, at 7:00 a.m. ET. Following the release, a conference call and live webcast will take place at 8:00 a.m. ET. Interested participants can register here.
The live webcast can be accessed on Teva's website. A replay will be available within 24 hours.
Teva Pharmaceuticals announced promising interim results from its Pan-European Real World study (PEARL) at the European Academy of Neurology Congress in Vienna. The study, evaluating the effectiveness of AJOVY® (fremanezumab) for chronic and episodic migraine, showed that 54.7% of the 389 patients analyzed experienced a reduction of 50% or more in monthly migraine days over six months. The study aims to provide real-world evidence to improve treatment access and outcomes for migraine patients across diverse European populations.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Auspex Pharmaceuticals have settled a patent dispute with Aurobindo concerning Aurobindo's ANDA for a generic version of Teva's AUSTEDO (deutetrabenazine). The agreement ends the litigation in the U.S. District Court for New Jersey, allowing Aurobindo to sell its generic product starting in April 2033 or earlier under specific conditions. Teva asserts the agreement underscores the strength of its intellectual property for AUSTEDO, which treats chorea associated with Huntington's disease and tardive dyskinesia.
Teva Pharmaceuticals has released results from a retrospective U.S. study demonstrating the effectiveness of AJOVY (fremanezumab-vfrm) in reducing monthly migraine days when used with gepants for acute treatment. At study initiation, patients averaged 15.8 monthly migraine days, which decreased by 6.5 days (41.1% reduction) post-treatment. This data, presented at the 2022 AHS Annual Meeting, highlights AJOVY's potential in managing migraines across diverse patient populations. However, 9.1% of patients reported adverse events, including injection site reactions and uveitis.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced eight abstracts on the use of AJOVY (fremanezumab-vfrm) for migraine treatment at the 2022 American Headache Society Annual Meeting in Denver, June 9-12. Key presentations include a late-breaking study on AJOVY's effectiveness with gepants for acute treatment and subgroup analysis from the Phase 3b FOCUS study. The findings aim to highlight AJOVY's impact on patients with specific migraine treatment needs, particularly during Migraine Awareness Month.
STADA is launching Hukyndra®, a high-concentration, citrate-free biosimilar to adalimumab, in select European markets including France, Germany, Finland, and Sweden. This launch follows approval from the European Commission and represents the first product from STADA's partnership with Alvotech. Hukyndra® is designed to enhance patient comfort with reduced injection-site pain. The biosimilar is approved for treating various inflammatory conditions, supporting patient access to vital therapies in Europe.
Teva Pharmaceuticals, in partnership with Direct Relief and the National Association of Free and Charitable Clinics, has launched a $2 million program to enhance access to mental health care for underserved populations. The initiative will provide funding over two years to free clinics while donating generic medications for anxiety and depression. Initially focused on Florida, New Jersey, and California, this program aims to address health equity issues exacerbated by the COVID-19 pandemic, supporting clinics to provide necessary resources and care for uninsured patients.
FAQ
What is the current stock price of Teva Pharm (TEVA)?
What is the market cap of Teva Pharm (TEVA)?
